Gene‐ and age‐informed screening for preclinical Alzheimer's disease trials

Introduction Elevated β‐amyloid is used to enroll individuals into preclinical Alzheimer's disease trials, but the screening process is inefficient and expensive. Novel enrichment methods are needed to improve efficiency of enrollment. Methods Alzheimer's disease incidence rates and a polygenic hazard score were used to create a gene‐ and age‐defined ADAge. An ADAge cutpoint was chosen to optimally predict β‐amyloid positivity among clinically...